CORT Share Price

Open 18.47 Change Price %
High 18.61 1 Day 0.09 0.49
Low 18.25 1 Week 0.47 2.62
Close 18.39 1 Month 0.88 5.03
Volume 698808 1 Year 11.45 164.99
52 Week High 20.77
52 Week Low 6.68
CORT Important Levels
Resistance 2 18.72
Resistance 1 18.59
Pivot 18.42
Support 1 18.19
Support 2 18.06
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
RITT 0.04 33.33%
SCHS 0.04 33.33%
RPRX 0.56 27.27%
ATRM 1.73 27.21%
BSDM 0.62 26.53%
TISA 1.63 26.36%
SNTA 0.34 25.93%
OTT 2.39 25.13%
DGLY 2.65 20.45%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DRRX 0.78 -60.41%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Corcept Therapeutics Incorporated (NASDAQ: CORT)

CORT Technical Analysis 4
As on 20th Oct 2017 CORT Share Price closed @ 18.39 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 11.62 & Buy for SHORT-TERM with Stoploss of 17.10 we also expect STOCK to react on Following IMPORTANT LEVELS.
CORT Target for October
1st Target up-side 21.27
2nd Target up-side 22.66
3rd Target up-side 24.04
1st Target down-side 17.33
2nd Target down-side 15.94
3rd Target down-side 14.56
CORT Other Details
Segment EQ
Market Capital 189395360.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.corcept.com
CORT Address
CORT
149 Commonwealth Drive
Menlo Park, CA 94025
United States
Phone: 650-327-3270
Fax: 650-327-3218
CORT Latest News
Interactive Technical Analysis Chart Corcept Therapeutics Incorporated ( CORT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Corcept Therapeutics Incorporated
CORT Business Profile
Corcept Therapeutics Inc is a United States-based pharmaceutical company. The Company is involved in the discovery and development of drugs that regulate the effects of cortisol or also known as the stress hormone. Founded on 1998, it has focused its research and clinical development activity on drugs that block the glucocorticoid receptor or GR-II receptor, one of the bodys two receptors of cotrisol. Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.